Healthcare Tips: Daiichi Sankyo to not proceed with lung cancer study

(Reuters) - Daiichi Sankyo Co Ltd said it will not proceed with the second part of its late-stage study on the lung cancer drug, patritumab.

Read more: Daiichi Sankyo to not proceed with lung cancer study